Amondys 45
Named-patient access overview. Amondys 45 is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Amondys 45 (casimersen) is a phosphorodiamidate morpholino oligomer (PMO) developed by Sarepta Therapeutics. The US Food and Drug Administration approved Amondys 45 in February 2021 under the accelerated approval pathway for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping, an estimated 8 percent of the DMD population. The drug is given by intravenous infusion once weekly at a dose of 30 mg/kg. Treatment is chronic and lifelong.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Amondys 45
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Amondys 45 is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Amondys 45 in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Amondys 45
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.